Alzinova AB (publ) (STO:ALZ)

Market Cap	76.71M -54.9%
Revenue (ttm)	25.66M +28.0%
Net Income	-26.58M
EPS	-0.26
Shares Out	154.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,053,879
Open	0.5230
Previous Close	0.5200
Day's Range	0.4890 - 0.5230
52-Week Range	0.3820 - 2.2800
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Alzinova AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. The company’s lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alz...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ALZ

Financial Performance

In 2025, Alzinova AB's revenue was 26.80 million, an increase of 59.44% compared to the previous year's 16.81 million. Losses were -26.27 million, 27.8% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error